title: Influence of neonatal opioid blockade or injections of gonadotrophin-releasing hormone on the timing of puberty in female rats: correlation of opioid effects with occupation of hypothalamic mu-opioid receptors.
abstract: Hypothalamic opioid peptides have been implicated in the timing of sexual maturation in several species. We have examined the effects of neonatal opioid blockade on the timing of puberty in the female rat and have compared these with the effects of neonatal GnRH injection. Intermittent naloxone (2.5 mg/kg) or GnRH (200 ng/100 g body wt) injected s.c. at 6-h intervals for the first 10 days of life only slightly advanced the mean day of vaginal opening (VO). However, the degree of precocity was significantly more marked in a subgroup of drug-injected rats. In contrast, injections of the long-acting opioid antagonist naltrexone (50 mg/kg) had no effect on the timing of VO. The results suggested that the duration of opioid receptor blockade is critical in determining the degree of opioid antagonist effect. Therefore, additional studies were performed to compare receptor occupancy of naloxone and naltrexone in 9-day-old rat pups. An ex-vivo binding assay was utilized to determine the availability of hypothalamic opioid-binding sites at various intervals following a single s.c. injection of antagonist. The time-course of inhibition of tritium labelled [D-Ala2-N-Me-Phe4,Gly5-ol]-enkephalin [( 3H]DAGO) binding (mu-opioid sites) revealed that naloxone occupies the mu-receptor for a relatively short period of time. Naloxone (2.5 and 50 mg/kg) produced extensive inhibition of [3H]DAGO binding at 30 min following injection but binding was 100% of control at 1 h and 3.5 h respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology and Biophysics, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: K M
authors.initials: KM
authors.lastname: Landymore
authors.forename: M
authors.initials: M
authors.lastname: Wilkinson
mesh_terms: D000818:Animals; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000494:pharmacology; D005260:Female; D007031:Hypothalamus / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology*; D009271:Naltrexone / Q000494:pharmacology; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology*; D051381:Rats; D011957:Receptors, Opioid / Q000378:metabolism; D017450:Receptors, Opioid, mu; D012741:Sexual Maturation / Q000187:drug effects*; D013997:Time Factors
chemical_list: D004745:Enkephalins; D010906:Pituitary Hormone-Releasing Hormones; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009270:Naloxone; D009271:Naltrexone